Lataa...
New survival standards for advanced melanoma
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing th...
Tallennettuna:
| Julkaisussa: | Br J Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group UK
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188675/ https://ncbi.nlm.nih.gov/pubmed/32063602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0738-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|